News

Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more
Mon, 29/04/2019
Publication: Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis.
Munich.  Here SFB researchers from Munich use in vivo calcium imaging in a multiple sclerosis model to show that cytoplasmic calcium levels determine the choice between axon loss and survival. Calcium can enter the axon through nanoscale ruptures of the axonal plasma membrane that are induced in inflammatory lesions. Neuron doi: 10.1016/ j.neuron.2018.12.023...more
Tue, 04/12/2018
SFB 128 International Symposium
SFB 128. We are happy to announce the international Symposium of the Collaborative Research Centre 128 “Multiple Sclerosis” taking place from Sunday, September 15th, till Tuesday, September 17th, 2019 in the Rhine Main region. Full details of the event will follow....more


Tue, 12/09/2017 | Genetically altered mice provide initial evidence that human gut bacteria can trigger multiple sclerosis

Munich. (LMU)  Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system. There are many indications that MS is an autoimmune disease in which immune cells “accidentally” attack the brain and spinal cord. However, as with other autoimmune diseases, the actual triggers of the autoimmune reaction are still unknown. A new study by scientists from the SFB 128 demonstrated for the first time that gut bacteria of MS patients are able to trigger an MS-like disease in an animal model. More . . .